Drugs / IGSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04842643 | Apr 2021 → Apr 2024 | immunodeficiency disease | Takeda | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-09-25 | Takeda | Regulatory Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia takeda.com ↗ |
| 2017-03-06 | Takeda | Results CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients’ Previous Immunoglobulin Therapy takeda.com ↗
Results demonstrated that after 12 months on CUVITRU, patients reported statistically significant improvements in the Treatment Interference and the Ther |
| 2016-09-23 | Takeda | Results SHIRE TO SHOWCASE CONTINUED INNOVATION AND LEADERSHIP IN IMMUNE DEFICIENCIES DURING EUROPEAN SOCIETY FOR IMMUNODEFICIENCIES BIENNIAL MEETING takeda.com ↗
Presentations will include results of studies examining the safety, efficacy and tolerability profiles of Shire’s IG treatment options for immune deficiencies, including primary immunodeficiency (PI). |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04842643 ↗ |
| Modality | Protein / enzyme biologic | “Immune Globulin Infusion (Human)” NCT04842643 ↗ |
| Route | Subcutaneous | “Immune globulin subcutaneous (IGSC) infusion” NCT04842643 ↗ |